BPC-157 Dosing: What the Published Research Actually Describes

why dosing is the wild west for this peptide

Walk into any peptide forum and ask what dose of BPC-157 to take. You'll get five confident answers from five different people. None of them will agree.

The reason isn't that everyone is making things up. There's just no single authoritative human dose-response study anyone can point at. What does exist: a large rat literature with a fairly consistent dosing range, a handful of small human trials that picked their own doses, and a long tail of anecdotal protocols that have been getting passed around online for a decade.

That's the actual state of the field. It's not a failure of peptide medicine — it's where things land when a molecule has spent most of its research life in animals and only recently started seeing human trials. The honest read is to know what's been published, where the gaps are, and to treat any specific number as best-guess based on what we have rather than as settled science.

where the numbers originally came from

Most of the BPC-157 dosing literature traces back to the Sikiric group at the University of Zagreb. Across hundreds of rat studies, the doses that produced effects sat roughly between 10 and 1,000 micrograms per kilogram per day, depending on the injury model and the route of administration.^[1]

A few patterns are worth knowing. The lower end (10-50 μg/kg) usually came from oral dosing — peptide dissolved in drinking water or given by gavage. The middle range (100-500 μg/kg) was typical for subcutaneous and intraperitoneal injections in injury-repair models: tendon tears, gut damage, muscle injury. The upper end (up to 1 mg/kg, sometimes higher) was used in extreme-stress models like ischemia-reperfusion injury, where researchers were essentially testing how far the peptide's protective effect would stretch.

What's striking when you read the rat literature as a whole is how flat the dose-response curve looks once you're inside that active range. The healing effects — smaller lesions, faster wound closure, better collagen organization — tend to plateau pretty early. Doubling the dose from 200 to 400 μg/kg often doesn't double the effect. That's clinically interesting because it suggests the molecule has a relatively wide therapeutic window in rats. Getting close to the right dose seems to matter more than getting it exactly right.

the math everyone gets wrong

Here's where the most common online dosing mistake shows up.

Someone takes a rat dose — say, 250 μg/kg — and just multiplies by their body weight to get a human dose. For a 70-kg adult, that math says 17.5 mg per day. That's much higher than what most actual human protocols have used.

The issue is that you can't directly scale mg-per-kg between species for almost any drug. Smaller animals have faster metabolism, faster drug clearance, and different surface-area-to-volume ratios. A dose that produces a given tissue concentration in a rat doesn't produce the same concentration in a human at the same per-kg dose. The standard correction is called allometric scaling — it uses body surface area instead of body weight — and it generally cuts rat doses by a factor of 6-10 when translating to humans.^[1]

Apply that correction and 250 μg/kg in a rat translates to closer to 25-40 μg/kg in a human. For our 70-kg adult, that's around 1.7-2.8 mg per day — which is much closer to what real human protocols have actually used. Online dosing guides that skip the scaling step are routinely recommending doses 5 to 10 times higher than what the underlying research supports.

what human studies have actually used

The published human data is limited. The most-cited trial is a Phase 1/2 study in knee osteoarthritis run by researchers affiliated with the Sikiric lab, using intraarticular injection plus oral administration.^[1] The oral arm used a few milligrams per day total — consistent with allometric scaling from the rat literature.

A handful of other trials sit on registries — small inflammatory bowel studies, a wound-healing study, a post-hand-surgery recovery study. Most haven't published full results yet. The doses across those trials cluster around 250-500 μg twice daily for oral, with similar ranges for subcutaneous in the trials that chose that route. Total daily exposure typically lands in the 0.5-2 mg range for oral and somewhat lower for injection (because injection bioavailability is higher).

The other source of human dosing data is what functional medicine clinicians did in the years when BPC-157 was legally compounded in the US (pre-2023). Compounding pharmacies generally formulated it at 250 μg or 500 μg per dose, with either twice-daily oral or once-daily subcutaneous as the typical regimen. Course duration was usually 4-8 weeks, sometimes longer for chronic gut indications.

oral vs injection — and the question of how oral even works

BPC-157 is a peptide. Stomach acid and digestive enzymes will tear most peptides apart if you swallow them like a regular pill. So how does oral BPC-157 work at all?

The answer that emerges from the literature is unusual: BPC-157 appears to be remarkably stable in gastric fluid. Probably because it was originally isolated from gastric juice — evolution has selected for stability there. Multiple studies have shown that oral administration in rats produces measurable systemic effects, even though the bioavailability is much lower than injection.^[1] The Sikiric group has published specifically on this — they argue BPC-157's structural stability in the gut is part of why it earned the name body protection compound in the first place.

The practical implication: oral works at higher doses, injection works at lower doses for the same effect. A 250-μg injection and a 500-μg or 1-mg oral dose may produce roughly comparable systemic exposure — though this hasn't been precisely characterized in humans. Many protocols accordingly bump the dose up on the oral side (500 μg to 1 mg) when oral is the chosen route.

why the research uses short courses, not open-ended daily use

One feature of the published research that doesn't always make it into online protocols: BPC-157 in studies is overwhelmingly used as a short, time-limited intervention. Most rat injury studies dose for 1-4 weeks. Most human protocols described in the available literature run 4-8 weeks for an acute indication, sometimes longer for chronic gut conditions.

What the research doesn't describe is open-ended daily use of BPC-157 the way someone might take a daily multivitamin. The mechanism story behind the peptide is repair-of-acute-injury — VEGF upregulation, tight-junction protein expression, granulation tissue support. These are processes that happen during a healing window, not continuous baseline maintenance.

The biohacker forum protocol of I take 500 μg of BPC-157 every day forever isn't really supported by the research design. It's not contraindicated either — long-term safety hasn't been formally characterized in humans, so we don't know one way or the other. But it's an extrapolation, not a research-backed protocol.

Clinicians who prescribed BPC-157 when it was legal generally treated it as a short-course intervention for a defined indication: a tendon injury, a documented gut permeability issue, a post-surgical recovery window. Once the indication resolved, the peptide stopped. That's how the research actually used it, and that's how prescribers used it in real practice.

what's genuinely unknown

Even with everything above, several things are still unsettled:

Is there a dose-response in humans? Rat studies show a relatively flat curve once you're in the active range. Whether the same is true in humans hasn't been demonstrated yet — there isn't enough human dose-range data to know.

Is twice-daily better than once-daily? Most protocols split the dose. The rationale is that the peptide has a short half-life, so splitting maintains more steady tissue levels. There's no published head-to-head comparison to confirm that actually matters for the repair effects.

Does the route really matter for the indication? Oral is convenient. Injection is faster-absorbing. For systemic indications (tendon, joint, muscle), there's no clear evidence that one route outperforms the other once the dose is matched for bioavailability. For local-gut indications, oral makes intuitive sense because the molecule contacts the target tissue directly.

Long-term safety. Most documented human use has been short-course (under 8 weeks). Whether daily use over months or years is safe is genuinely unknown. The peptide has a clean acute safety profile, but absence of evidence isn't evidence of absence for chronic exposure.

where this leaves you

If you're trying to understand BPC-157 dosing from the published research, the honest summary:

- Rat studies cluster at 10-1000 μg/kg, with most effects in the middle of that range - Human protocols (small trials and prior compounding-pharmacy practice) typically used 250-500 μg per dose, twice daily, for 4-8 weeks - Allometric scaling means rat per-kg doses don't translate directly — typical human exposure is 0.5-2 mg total per day, not 10-20 mg - Oral works but at roughly 2-4x the injection dose for similar systemic exposure - Open-ended daily use isn't what the research describes — short courses for defined indications are the actual evidence base

What's not in this article: a recommendation for what dose YOU should take. That's not a research question. It's a clinical question that depends on your specific indication, history, body weight, route preference, and a lot of other factors that a prescriber weighs when this peptide is legally prescribable.

As of mid-2026, BPC-157 is on the FDA's Category 2 bulk drug substances list — 503A compounding pharmacies can't legally produce it. The administration announced intent in February 2026 to move 14 peptides (BPC-157 among them) back to Category 1. As of this writing, that reclassification hasn't formally published. Until it does, the legitimate path for a US patient interested in this peptide is to wait for the regulatory move and have the dosing conversation with a prescriber once it lands.

For more on the regulatory landscape, see are peptides legal in 2026. For a research read on what BPC-157 might do for the gut specifically, see BPC-157 for leaky gut.